How to Value a Healthcare IT Company in 2026

Healthcare IT sits at the intersection of two sectors that command premium valuations — healthcare and technology. Having spent years advising on transactions in both spaces, I can tell you that healthcare IT companies consistently punch above their weight in M&A, but only when they understand what makes their business valuable to a buyer.

Our database includes 483 healthcare IT transactions with a median EBITDA multiple of 16.47x and revenue multiple of 3.6x. The sector is growing and attracting significant capital. But not all healthcare IT is valued equally — the difference between a 4x revenue deal and a 12x revenue deal comes down to a handful of specific factors that I'll walk through here.

The Healthcare IT Landscape

Healthcare IT is a broad category, and buyers segment it carefully. Each sub-sector has its own valuation dynamics:

EHR/EMR vendorsare the backbone of healthcare IT. Epic and Cerner (now Oracle Health) dominate the enterprise market, but there are hundreds of specialty-specific EHR vendors serving niches like ophthalmology, behavioral health, long-term care, and dental. These niche EHR companies are enormously attractive acquisition targets because they're sticky — switching EHR systems is one of the most painful transitions in healthcare — and they generate predictable recurring revenue.

Revenue cycle management (RCM) companies handle billing, coding, claims processing, and collections. This is a massive market being disrupted by automation and AI. RCM firms with technology-enabled service delivery (think: AI-assisted coding, automated denial management) command materially higher multiples than those relying purely on manual processes. The margin profile tells the story — tech-enabled RCM runs 25-40% EBITDA margins versus 8-15% for labor-intensive shops.

Healthcare analytics and population healthplatforms help payers and providers identify high-risk patients, manage care quality, and reduce costs. This category has exploded with the shift to value-based care models. Companies with proprietary datasets or algorithms that demonstrably reduce cost of care attract the highest multiples I've seen in healthcare IT.

Telehealth platforms experienced extraordinary growth during COVID and then a correction. The market is now maturing, and valuations have normalized. Companies that survived the correction with strong retention and real clinical integration (not just video visits) are well-positioned.

Clinical decision support and patient engagement tools round out the category. These range from clinical trial matching platforms to patient portal solutions. Valuations vary widely based on how deeply integrated the product is in clinical workflows.

The Regulatory Moat

Here is what makes healthcare IT fundamentally different from general enterprise software, and why I think it deserves its premium: regulation creates moats that are almost impossible to replicate quickly.

HIPAA compliance isn't just a checkbox — it requires specific technical architecture, operational procedures, employee training, and audit trails. ONC Health IT certification for EHR products is a multi-year, multi-million-dollar process. The 21st Century Cures Act's interoperability requirements have raised the bar even further, requiring certified health IT to support open APIs and prohibit information blocking.

For buyers, these regulatory requirements translate directly into barriers to entry. A startup can't just build a better EHR and expect to compete — it needs years of certification work and compliance infrastructure. That's why acquirers pay premium multiples: they're buying regulatory compliance that would take years and millions to build from scratch.

KLAS ratings deserve special mention. For EHR vendors, KLAS performance scores are the industry's equivalent of a Consumer Reports rating. A top-tier KLAS rating in your specialty category is worth real money in a transaction because it directly impacts sales velocity and customer confidence.

Size Dynamics and the PE Wave

The size effect in healthcare IT is dramatic. Our data shows companies under $5M in enterprise value trade at 5.81x EBITDA and 1.33x revenue. The $5-25M bracket jumps to 8.55x EBITDA and 1.85x revenue. Larger deals command significantly higher multiples, driven by the massive amount of PE capital targeting the space.

Private equity has flooded into healthcare IT over the past decade, and the buy-and-build model is now the dominant M&A strategy. A typical PE playbook: acquire a platform healthcare IT company at 10-14x EBITDA, make 3-5 bolt-on acquisitions at 6-9x to add product capabilities or customer segments, integrate everything onto a common platform, and exit at 15-20x EBITDA as a comprehensive solution. If a PE firm is approaching you, understanding whether you're the platform or the bolt-on is critical to your negotiation.

Key Valuation Metrics Buyers Scrutinize

Beyond standard SaaS metrics like ARR and net retention, healthcare IT buyers focus on sector-specific KPIs:

Lives or providers on platform. This metric captures market penetration in a way revenue alone cannot. A company managing 2 million covered lives or supporting 15,000 active providers has network effects and scale advantages that a revenue number doesn't fully convey. Buyers love this metric because it indicates growth runway.

Recurring revenue percentage. The threshold for premium valuation in healthcare IT is 80%+ recurring revenue. Below 70%, buyers start discounting heavily because it signals a services-heavy model. The best healthcare IT companies I've valued are 85-95% recurring.

Client retention and revenue retention. Logo retention above 95% is expected in healthcare IT because switching costs are so high. But revenue retention is the more telling metric — are existing clients expanding their spend? Net revenue retention above 110% signals that your product is becoming more embedded and valuable over time, which is exactly what buyers want to see.

Regulatory certifications. ONC certification, SOC 2 compliance, HITRUST certification — each of these represents years of investment and serves as competitive insulation. A comprehensive list of certifications can add real multiple expansion to your deal.

The Interoperability Premium

The 21st Century Cures Act has fundamentally reshaped healthcare IT by mandating interoperability through FHIR APIs and prohibiting information blocking. Companies that have leaned into this trend rather than resisting it are being rewarded by the market.

I've seen acquirers pay meaningful premiums for healthcare IT companies with mature API ecosystems, active integration partnerships, and FHIR-native architectures. The logic is simple: interoperability mandates are only going to get stricter, and companies that have already built for interoperability have a multi-year head start on those scrambling to comply.

Conversely, companies with closed, proprietary architectures that resist data sharing are seeing valuation compression. What was once a competitive advantage (locking in customers through data silos) is now a regulatory liability and a red flag for sophisticated buyers.

What Drives Healthcare IT Value Up

Deep specialty focus. Counterintuitively, narrow specialization often commands higher multiples than broad horizontal platforms. A best-in-class EHR for dermatology or behavioral health is more valuable than a mediocre general-purpose EHR because specialty buyers will pay for domain expertise and purpose-built workflows.

Proprietary data assets. If your platform generates or aggregates unique clinical or claims data that can power analytics, research, or AI applications, that data is independently valuable. Some healthcare M&A deals are structured partly as data acquisitions.

AI and automation capabilities. Healthcare IT companies with production AI — clinical documentation, coding automation, predictive analytics, imaging analysis — are commanding significant premiums in 2026. The key word is "production" — buyers want AI that's deployed, validated, and generating measurable value, not science projects.

Value-based care enablement. The shift from fee-for-service to value-based care is the dominant trend in healthcare economics. Companies whose software enables risk-based contracting, quality measurement, or care coordination for value-based models are aligned with the future of the industry, and buyers price that alignment in.

What Kills Healthcare IT Value

Implementation complexity. If every new customer requires 6-12 months of custom implementation, your company looks more like a services firm than a software company. Buyers will apply services multiples to that revenue regardless of what you call it.

Customer concentration in healthcare systems. Landing a large health system as a customer is great, but if one IDN represents 25%+ of your revenue, you have a concentration risk that any healthcare buyer will scrutinize and discount.

Technical debt and legacy architecture. Healthcare IT companies that haven't modernized their tech stack face double jeopardy: buyers see both a capital expenditure requirement and a regulatory risk (legacy systems are harder to secure and certify).

The Bottom Line

Healthcare IT is one of the most attractive sectors in M&A, combining the recurring revenue characteristics of software with the regulatory moats and mission-critical nature of healthcare. The 16.47x median EBITDA multiple in our database reflects that premium positioning, and the sector's growth trajectory suggests multiples will remain strong.

If you're building or running a healthcare IT company, the path to maximum valuation is clear: high recurring revenue, deep regulatory compliance, strong customer retention, interoperability-forward architecture, and a credible AI or automation story. Companies that check all five boxes are the ones generating the headline-making multiples. Those missing two or more are leaving substantial value on the table.